Lisa’s Favorite Profit Producing Strategies & Tactics – Monthly Mastermind January 2024

Links Mentioned:
Solubiomix Pharmacy Brochures: https://drive.google.com/drive/folders/1CsFB5yz1hxa3TKww18bcVleIkIjskHdK
Solubiomix Physician Brochures: https://drive.google.com/drive/folders/1zvucZ__ARGr3B-zRAnnQYrFYBrM9GWac

**NOTE** – Tesofensine was approved by the FDA as a part of Tesomet as an orphan drug designation. There is division among compounders regarding whether the orphan drug status allows Tesofensine to meet the requirements to compound with. Some say yes, and some say no. You will need to decide for your pharmacy.

Summary:

Lisa Faast discussed strategies for mitigating reimbursement losses in pharmacies, emphasizing direct billing for workers’ compensation and hospice, which bypass PBMs and offer full reimbursement rates. She highlighted the profitability of direct billing, citing examples like omeprazole, which increases from $1.88 to $5.96 when billed directly. Faast also promoted RPM and CCM programs, noting their effectiveness in early intervention and cost savings. She introduced higher margin prescriptions, including alcohol swabs, clemastine, coxsanto, and nitrivia, and stressed the importance of bargain hunting on Match RX for cost savings.

Action Items

Outline

Reimbursement Challenges and Profitable Strategies

Direct Billing Workers Compensation

Direct Billing Hospice

RPM and CCM Programs

Higher Margin Prescriptions

Weight Loss Compounding Tactics

Sterile Compounding and Growth Strategies

Bargain Hunting with Match RX

Member Perks and Support

Q&A and Closing Remarks